5 Small Cap Stocks with Potential to Rise 1000 Percent

Page 5 of 5

1. Silence Therapeutics plc (NASDAQ:SLN)

Silence Therapeutics plc (NASDAQ:SLN) is one of the small-cap stocks with potential to rise 1000 percent. The company’s lead story is divesiran, an experimental treatment for polycythemia vera, a rare blood cancer in which the body makes too many red blood cells. Patients often need repeated blood draws to lower red blood cell levels, and Silence is trying to reduce that treatment burden with a drug designed to turn down a disease-related gene signal.

On June 11, Silence presented follow-up Phase 1 data from the SANRECO study at the European Hematology Association 2026 Congress. In the six months before treatment, 21 patients needed 80 blood draws. During active treatment, that number fell to 5, and only 4 more blood draws were reported during the 16-week follow-up period after the final dose. Among 14 patients with longer follow-up, the median time to the first blood draw was 287 days.

The next test is larger. Silence said its Phase 2 SANRECO study remains on track for top-line results in August 2026. The company ended the first quarter with $70.1 million in cash, cash equivalents, and short-term investments.

Silence Therapeutics plc (NASDAQ:SLN) is a clinical-stage biotechnology company developing RNA-based medicines for blood disorders, cardiovascular disease, and rare diseases.

While we acknowledge the potential of SLN to grow, our conviction lies in the belief that some other AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLN and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 5 of 5
1281292 - 11759070 - 1